A new report from IQVIA Institute for Human Data Science estimates that of 7,310 prescription drugs legally dispensed to U.S. patients between January 2017 to December 2022, roughly 70% (5,085) were being actively marketed and sold by illegal online pharmacies.

FDA has approved buprenorphine extended-release injection (Brixadi—Braeburn) for the treatment of moderate to severe opioid use disorder (OUD). The drug is available as a weekly dose for patients who have started treatment with a single dose of a transmucosal buprenorphine product and as a monthly version for patients already being treated with buprenorphine.

Findings from a study published in NEJM suggest that a key treatment for opioid use disorder is underprescribed among patients in the United States, in particular among Black patients.